Boult Wade Tennant
/sectors

Sector: Biotechnology

March 13, 2025

Multidrug-resistant bacteria discovered in space

Microbes are ubiquitous here on Earth and can survive a range of environmental conditions encompassing broad ranges of temperature, pH, salinity, energy,

February 11, 2025

Women scientists who inspire us at Boult

Today is the UN’s International Day of Women and Girls in Science. It’s fair to say that, in modern science, we stand

January 13, 2025

International Year of Quantum Science and Technology

Welcome to 2025 – the ‘International Year of Quantum Science and Technology’ – but what are Quantum Technologies? Welcome to 2025! This

November 7, 2023

New insights into mRNA technologies

Do you have an interest in mRNA technologies, in particular mRNA vaccines? The European Patent Office (EPO) has published an insight report

July 24, 2023

Plant Breeders Rights – action required on Retained EU Plant Variety Rights in the UK.

Following the UK’s exit from the European Union (EU), Retained EU Plant Variety Rights were awarded to provide continuing protection in the

June 23, 2023

Proposals for reform of the EU’s SPC system.

On 27 April 2023 the European Commission published proposals concerning supplementary protection certificates (SPCs) for medicinal products and plant protection products. SPC protection

March 27, 2023

G2/21.

The Enlarged Board of Appeal of the European Patent Office issued the decision in referral G2/21 on 23 March 2023. This referral concerned the admissibility of post-published evidence in the assessment of inventive step.

February 9, 2023

Clinical trials and prior disclosure – a difficult balancing act for patentees.

The European Patent Office (EPO) has recently ruled that patients in a clinical trial were not members of the public such that

October 21, 2022

From the G 2/21 preliminary opinion.

Plausibility: Insights from the G 2/21 preliminary opinion The EPO’s Enlarged Board of Appeal (EBA) referral G 2/21 will hopefully clarify the

January 11, 2022

Plausibility and Post-Published Evidence (G2/21).

The Enlarged Board of Appeal of the European Patent Office has been challenged with a new referral (G2/21) concerning the admissibility of